Bioceltix (WAR:BCX) Total Liabilities: zł3.02 Mil (As of Mar. 2026)


WAR:BCX Bioceltix SA WAR:BCX
26 GF Score
Price zł89.70
! 1 Warning Sign
View Full Analysis

What is Bioceltix Total Liabilities?

Bioceltix WAR:BCX -0.77% 26 Total Liabilities is zł3.02 Mil as of Mar. 2026. GuruFocus rates WAR:BCX with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Bioceltix's Total Liabilities for the quarter that ended in Mar. 2026 was zł3.02 Mil.

Bioceltix's quarterly Total Liabilities declined from Sep. 2025 (zł3.16 Mil) to Dec. 2025 (zł2.36 Mil) but then increased from Dec. 2025 (zł2.36 Mil) to Mar. 2026 (zł3.02 Mil).

Bioceltix's annual Total Liabilities increased from Dec. 2023 (zł2.27 Mil) to Dec. 2024 (zł2.31 Mil) and increased from Dec. 2024 (zł2.31 Mil) to Dec. 2025 (zł2.36 Mil).

Bioceltix Total Liabilities Historical Data

* Premium members only.

The historical data trend for Bioceltix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix Total Liabilities Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 2.20 2.50 2.27 2.31 2.36

Bioceltix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 3.46 3.16 2.36 3.02
WAR:BCX
26GF Score
Bioceltix SA WAR:BCX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioceltix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bioceltix's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.193+(0.088+0.065
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.009+0)
=2.36

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=75.632-73.276
=2.36

Bioceltix's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.885+(0.064+0.066
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.009+0)
=3.02

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=70.614-67.591
=3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of zł3.02 Mil mean?
Bioceltix (WAR:BCX) has a Total Liabilities of zł3.02 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bioceltix and its competitors.
Is Bioceltix's Total Liabilities too high?
Bioceltix's current Total Liabilities is zł3.02 Mil. Overall, Bioceltix has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's Total Liabilities compare to VRTX and REGN?
Bioceltix's Total Liabilities of zł3.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bioceltix and its competitors. Bioceltix's current Total Liabilities is zł3.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current Total Liabilities of zł3.02 Mil. The current Total Liabilities is zł3.02 Mil. Bioceltix's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current Total Liabilities is zł3.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioceltix Business Description

Address Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
26GF Score

Get the complete analysis for WAR:BCX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł89.70
Price